Shades of T790M: Intratumor Heterogeneity in EGFR-Mutant Lung Cancer

Eiki Ichihara, Christine M. Lovly

Research output: Contribution to journalComment/debate

11 Citations (Scopus)

Abstract

In the setting of recent exciting clinical results and numerous ongoing trials, Piotrowska and colleagues explore mechanisms of acquired resistance to the mutant-specific EGFR inhibitor rociletinib, and demonstrate that loss of T790M, EGFR amplification, and small-cell transformation are all clinically relevant mechanisms of drug resistance. The authors provide a new paradigm for using quantitative assessment of the EGFR T790M:activation mutation allele frequency ratio to prognosticate responses to rociletinib and also demonstrate that plasma-based assessments of circulating tumor DNA can be used to monitor drug response and the emergence of drug resistance.

Original languageEnglish
Pages (from-to)694-696
Number of pages3
JournalCancer discovery
Volume5
Issue number7
DOIs
Publication statusPublished - Jul 1 2015

    Fingerprint

ASJC Scopus subject areas

  • Oncology

Cite this